Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Airbus Joins Air India A320 Altitude Drop Probe 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
US Judge Dismisses Gautam Adani Criminal Charges 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
India’s top drugmakers, Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN), are moving closer to developing affordable anti-obesity drugs as the country faces a growing health crisis. According to Mint, both companies have received approval from the Drugs Controller General of India (DCGI) to advance their obesity drug programs, aiming to provide cost-effective alternatives to expensive global treatments.
Sun Pharma has been cleared to launch a large-scale Phase III clinical trial for its oral semaglutide tablets, a promising development given the high demand for easier-to-use, non-injectable options. Meanwhile, Lupin has secured approval for a bioequivalence study to prove that its generic obesity pill performs similarly to the original version. These steps could pave the way for wider patient access in a market where obesity treatment remains limited and costly.
Currently, breakthrough drugs like Novo Nordisk’s Wegovy (CSE:NOVOb) and Eli Lilly’s Mounjaro (NYSE:LLY) are available but are prohibitively priced and largely limited to injections, restricting accessibility for many Indian patients. With generics entering the pipeline, experts suggest that treatment costs could drop significantly, improving access to millions struggling with obesity. However, doctors caution that misuse of such medications could pose risks, stressing the importance of strict medical supervision and regulatory safeguards.
India is facing a mounting obesity epidemic. A Lancet study projects the country could have nearly 450 million overweight and obese adults by 2050, putting immense pressure on its healthcare system. The push by Sun Pharma and Lupin to create affordable anti-obesity solutions could mark a turning point in tackling this challenge, offering new hope for patients while reinforcing India’s position in the global pharmaceutical market.
